Company / R&D per Share
Summit Therapeutics Inc. R&D per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.72
FY2025
5-year range
$0.21 / $0.87
FY2021-FY2025
Trend
+234.6%
vs FY2024
Sector context
#160 of 208
Health Care
What the data says
R&D per Share changed +235% YoY in FY2025, a notable deviation from the 7-year average annual change of +32%.
Based on SEC 10-K filings.
0.72 in FY2025 with a 5-year CAGR of -1.9%.
Improved from $0.28 to $0.72 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -6.2%
- 5-Year CAGR
- -1.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 208This company $0.72 Sector average $28.82
▼
-97.5% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 234.6% year-over-year.
- Ranks #160 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
- Lowest r&d per share in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.72 | +234.6% |
| FY2024 | $0.21 | -23.7% |
| FY2023 | $0.28 | -67.6% |
| FY2022 | $0.87 | +242.9% |
| FY2021 | $0.25 | -68.0% |
| FY2020 | $0.79 | -34.6% |
| FY2019 | $1.21 | -59.8% |
| FY2018 | $3.02 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026